These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2328507)

  • 1. Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile.
    McHale DM; Sage JI; Sonsalla PK; Vitagliano D
    Clin Neuropharmacol; 1990 Apr; 13(2):164-70. PubMed ID: 2328507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dystonia in Parkinson's disease: clinical and pharmacological features.
    Poewe WH; Lees AJ; Stern GM
    Ann Neurol; 1988 Jan; 23(1):73-8. PubMed ID: 3345068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin.
    Pacchetti C; Albani G; Martignoni E; Godi L; Alfonsi E; Nappi G
    Mov Disord; 1995 May; 10(3):333-6. PubMed ID: 7651452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics of painful dystonic foot response in patients with Parkinson's disease].
    Hara H; Wakayama Y; Kawase J
    Rinsho Shinkeigaku; 1989 Sep; 29(9):1101-5. PubMed ID: 2598534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dystonia and Parkinson's disease.
    Carella F; Giovannini P; Girotti F; Testa D; Caraceni T
    Adv Neurol; 1993; 60():558-61. PubMed ID: 8420191
    [No Abstract]   [Full Text] [Related]  

  • 7. Levodopa-associated hemifacial dystonia.
    Mark MH; Sage JI
    Mov Disord; 1991; 6(4):383. PubMed ID: 1758464
    [No Abstract]   [Full Text] [Related]  

  • 8. Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology.
    Poewe W; Lees AJ; Steiger D; Stern GM
    Adv Neurol; 1987; 45():357-60. PubMed ID: 3825711
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
    Stern MB; Vernon GM; Gollomp SM; Hurtig HI
    Bull Clin Neurosci; 1986; 51():52-6. PubMed ID: 3455244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 11. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea.
    Sage JI; Mark MH; McHale DM; Sonsalla PK; Vitagliano D
    Ann Neurol; 1991 Jun; 29(6):623-8. PubMed ID: 1892365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy.
    Shan DE; Kwan SY; Ho HH; Su MS
    Mov Disord; 1996 Jul; 11(4):455-7. PubMed ID: 8813234
    [No Abstract]   [Full Text] [Related]  

  • 14. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa and executive performance in Parkinson's disease: a randomized study.
    Pascual-Sedano B; Kulisevsky J; Barbanoj M; García-Sánchez C; Campolongo A; Gironell A; Pagonabarraga J; Gich I
    J Int Neuropsychol Soc; 2008 Sep; 14(5):832-41. PubMed ID: 18764978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is levodopa toxic to human substantia nigra?
    Rajput AH; Fenton Me; Birdi S; Macaulay R
    Mov Disord; 1997 Sep; 12(5):634-8. PubMed ID: 9380042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinsonism following dystonia in three patients.
    Katchen M; Duvoisin RC
    Mov Disord; 1986; 1(2):151-7. PubMed ID: 3504239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Square-wave action dystonia in Parkinson's disease.
    van den Munckhof P; Lenz FA; Chase TN
    Mov Disord; 1998 Mar; 13(2):354-6. PubMed ID: 9539355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.